Fairvalue-Calculator Fairvalue-Calculator
EN DE

SoftOx Solutions AS, (SOFTX) Fair Value & Analysis

Healthcare · NO · Market cap 283M NOK

Pricekr 0.1078
Fair Valuekr 0.0400
Upside-62.9%
Quality95/100
Evidence: Low Range kr 0.0300 – kr 0.0500

Fair value as of: Jun 24, 2026

Analysis

SoftOx Solutions AS, (SOFTX) currently trades at kr 0.1078, while our model-based Fair Value estimate is kr 0.0400 — implying the stock looks roughly 62.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program that is in phase 2a to treatment of chronic airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, yeast, spores, and fungi. SoftOx Solutions AS was founded in 2012 and is based in Lysaker, Norway.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is SoftOx Solutions AS, (SOFTX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 0.0400 versus a price of kr 0.1078 — about −63% (overvalued). Model-based estimate, not financial advice.
What is the fair value of SOFTX?
Our 21-model fair value for SoftOx Solutions AS, is kr 0.0400 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 0.1078.
What is the quality score of SOFTX?
SoftOx Solutions AS, has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.